
Northern Lights Tonight: 14 States May See Aurora After Coronal Mass Ejection
A geomagnetic storm watch is in place for July 1-2, 2025.
The Northern Lights may be visible in the U.S. overnight on Tuesday and Wednesday as a coronal mass ejection travels towards Earth to cause a geomagnetic storm, according to the latest forecast by the National Oceanic and Atmospheric Administration's Space Weather Prediction Center. It follows several displays of aurora in northern U.S. states in recent weeks.
NOAA's three-day forecast includes a minor geomagnetic storm, measured at a value of G1 on a scale of G1 to G5. According to NOAA's forecast, the Kp index — which provides a rough guide to the intensity of aurora displays — may reach 5.
When To See The Northern Lights Tonight
The G1 geomagnetic storm is set to peak between 11:00 p.m. on Tuesday, July 1 and 5:00 a.m. on Wednesday, July 2. This forecast — which is subject to change — means the geomagnetic storm will coincide with the limited hours of darkness in all U.S. time zones.
'A G1 (Minor) geomagnetic storm watch has been issued for 02 Jul (UTC day) due to the arrival of a CME that left the Sun on 28 Jun,' stated NOAA on X (Twitter). A coronal mass ejection is a cloud of super-charged particles released by the sun. The timing agrees with a NASA model. Professional aurora chaser Vincent Ledvina described it on X (Twitter) as 'not too crazy, but something to keep an eye on.'
NOAA's aurora viewline forecast for the early hours of July 2, 2025.
Where To See The Northern Lights
NOAA's aurora viewlines indicate potential aurora displays are possible in northern U.S. states and Canada. U.S. states that may see aurora include (northerly parts of) Washington, northern Idaho, Montana, Wyoming, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Iowa, New York, Vermont, New Hampshire and Maine. In the U.S., regions close to the Canadian border will have the highest chance.
However, limited darkness at these latitudes may reduce visibility, despite the aurora potential. The recent solstice means it doesn't get completely dark at night in late June near the U.S.-Canada border — and not at all in Alaska.
On Tuesday, the moon — in its waxing crescent phase — will be 43%-lit, so aurora chasers will also have to contend with some natural light pollution.
What Happened To 'Solar Maximum'
The Northern Lights are caused by the solar wind, a stream of charged particles from the sun interacting with Earth's magnetic field. Charged particles accelerate along the magnetic field lines toward the polar regions, where they collide with oxygen and nitrogen atoms, exciting them and causing them to release energy as light.
The sun has an 11-year cycle during which its magnetic activity — and its propensity to produce solar flares and CMEs — peaks and troughs. The solar maximum period may be coming to an end, with the number of sunspots on the sun — which indicates how magnetically active it is — dropping off in June.
That could indicate that the sun is now past just the solar maximum phase (though sunspot numbers can fluctuate). However, the best aurora displays often occur in the few years after solar maximum. If the current solar cycle does have a long tail, good aurora sightings in the U.S. could result for a few years.
An aurora borealis, also known as the northern lights, is seen in the night sky in the early morning ... More hours of Monday, April 24, 2023, near Washtucna, Wash. (AP Photo/Ted S. Warren)
When The Northern Lights Are Most Common
March-April and September-October are the most geomagnetically active months of the year, with geomagnetic disturbances twice as likely in spring (and also in fall) as in winter and summer. They tend to be strongest a week or two after the equinoxes (Sept. 22, 2025, and March 20, 2026).
Earth's axis tilts by 23.5 degrees, which is why we have seasons. It also puts Earth perpendicular to the sun at the equinox. Since the solar wind's magnetic field is facing southward relative to the Earth, during the equinox, the geometry more easily allows charged particles from the sun to be accelerated down the field lines of the Earth's magnetic field.
Wishing you clear skies and wide eyes.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Is it going to rain in Phoenix? Record heat could give way to a chance of showers
Storm activity could start brewing across metro Phoenix after a record-high start to the week, but don't expect monsoon season to start with a bang. Moisture is edging into Arizona as temperatures heat up, but storms will likely develop over higher terrain east and southeast of Phoenix. The region might see some gusty winds or blowing dust late on July 1, but widespread rainfall remains unlikely so far. The high temperature on June 30 reached 116 degrees, 1 degree above the old record set in 2013 and 1979. Heat can be an important factor in the onset of monsoon showers, though it's no guarantee. "The Phoenix metro will only see about a 10 to 15% chance during the evening into the overnight hours on Tuesday," said Alex Young, a lead meteorologist for the National Weather Service in Phoenix. "There are some better chances on Wednesday as the moisture is peaking across the area." The odds for rain are slightly higher for July 2, with a 15% to 30% chance of showers in Phoenix. This could bring isolated storms and dust to parts of the Valley. "This increase in activity across eastern and southeastern Arizona will kick up some good dust with some gusty winds," Young said. "We'll have to monitor how things go down in southeastern Arizona and what they might send up our way Tuesday evening." The atmosphere will dry out again by July 3, but the surge of moisture will alleviate high temperatures heading into the July 4 holiday weekend. The National Weather Service issued extreme heat warnings through July 1, with lower deserts projected to have temperatures up to 117 degrees. Temperatures will start to drop and trend near or slightly below normal over the holiday weekend, providing a reprieve for holiday picnics and poolside plans. "For the 4th of July, it looks like no real chances of showers or thunderstorm activity," Young said. "Our highs are going to be in the lower 100s." Hayleigh Evans writes about extreme weather and related topics for The Arizona Republic and Email her with story tips at This article originally appeared on Arizona Republic: Phoenix-area weather: High temps could finally usher in monsoon storms


Medscape
33 minutes ago
- Medscape
Gastric Procedure Alleviates GERD Symptoms in Obesity
TOPLINE: In patients with obesity, endoscopic gastric remodeling (EGR) — a minimally invasive procedure — is safe and effective in relieving both typical and atypical gastroesophageal reflux disease (GERD) symptoms at 12 months post-procedure, while also reducing proton pump inhibitor (PPI) use. METHODOLOGY: EGR is a minimally invasive alternative to bariatric surgery that reduces gastric volume by approximately 70%, though its effect on GERD symptoms remains unclear. Researchers conducted a prospective cohort study at a tertiary referral bariatric center to examine EGR's effect on GERD symptoms in patients with at least one obesity-related comorbidity. Patients completed GERD and health-related assessments before and 12 months after the procedure. TAKEAWAY: Researchers included 50 patients (mean age, 41 years; mean BMI at baseline, 38.4; 95.8% women; 44% with GERD) who underwent EGR using either endoscopic suturing (16%) or plication (84%). All patients successfully underwent EGR without any serious adverse events. Between baseline and 12 months post-procedure, the mean Reflux Symptom Index score decreased from 5.1 to 3.8 (P = .007) and PPI use from 38% to 20% (P = .047). The presence of a hiatal hernia predicted a greater alleviation of GERD symptoms. IN PRACTICE: 'EGR may be considered a preferred option to co-manage both obesity and GERD, particularly in the lower obesity class,' the authors wrote. SOURCE: This study was led by Pichamol Jirapinyo, MD, MPH, Brigham and Women's Hospital, Boston, and published online in Clinical and Translational Gastroenterology. LIMITATIONS: This study did not include esophageal pH monitoring before or after EGR. Most participants were non-Hispanic women, which may have limited generalizability. Factors such as dietary modifications and medication use were not assessed. DISCLOSURES: The study received no external funding. Several authors reported being consultants; receiving research support, grants, or royalties; and having other ties with pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a 'high-risk, high-reward' clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T therapy that overcomes limitations with current options. Currently approved therapies of this kind act by upgrading patient-extracted T cells' ability to fight cancer cells, but this method has financial and scalability hurdles, along with a lymphodepleting chemo requirement, curbing uptake. Capstan's lead asset, CPTX2309, is an in vivo targeted lipid nanoparticle (LNP) anti-CD19 CAR-T therapy that could solve these issues. AbbVie certainly sees the promise in the drug, paying $2.1bn upfront to take control of the CAR-T therapy alongside other preclinical programmes and the RNA payload-delivering technology used to create them. CPTX2309, being developed for the treatment of B-cell-mediated autoimmune diseases, is already being evaluated in a Phase I study (NCT06917742) with healthy volunteers. A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an 'immune reset' by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made. The big pharma has a market cap of $327.9bn. This is not the first in vivo CAR-T relationship that AbbVie has fostered, with a collaboration with Umoja Biopharma in January 2024. This partnership allows AbbVie to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's VivoVecplatform. William Blair analyst Matt Phipps said in a research note: 'While CPTX2309 is still in early clinical development, we believe the acquisition shows a strategic effort by AbbVie to further strengthen its immunology franchise through novel, disease-modifying mechanisms. 'Given the stage of development, this asset clearly comes with clinical risk, but given the potential of in vivo CAR-T, which does not require lymphodepletion and has potential for greater manufacturing scalability, it offers significant long-term upside if successful.' Phipps, who described AbbVie's new asset as 'high-risk, high-reward,' said the purchase consolidates AbbVie's strong trading. The big pharma company has already shrugged off the loss of market exclusivity for its blockbuster Humira (adalimumab) by rolling out Skyrizi (risankizumab) and Rinvoq (upadacitinib). According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an 'attractive opportunity' for long-term investors. Capstan's CEO Laura Shawver said: "In vivo CAR-T represents a potential new treatment modality in medicine – embodying the transformative power of cell therapy with the accessibility and scalability of an off-the-shelf biologic. This technology has the potential to become a first-in-class platform to treat a wide range of autoimmune diseases.' Interius BioTherapeutics and Umoja Biopharma are two biotechs in the in vivo CAR-T arena that have assets in clinical trials targeting oncological indications. These assets also use lentiviral vectors to generate the cells in vivo, whereas Capstan is using mRNA. CPTX2309 is built on Capstan's targeted LNP platform to enable in vivo delivery of RNA payloads to target cells. CPTX2309 is made up of an anti-CD19 CAR mRNA payload inside an LNP. AbbVie's purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector's outlook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. "AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data